Odyssey Therapeutics Appoints H. Martin Seidel, Ph.D., to Scientific Advisory Board [Yahoo! Finance]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology, today announced the appointment of H. Martin Seidel, Ph.D., to its Scientific Advisory Board. Dr. Seidel is a highly accomplished drug discovery and development leader with decades of experience spanning biotechnology and large pharmaceutical organizations. He currently serves as Chief Executive Officer of IFM Therapeutics, where he has overseen the advancement of multiple discovery and development programs and three successful portfolio company exits. Prior to IFM, Dr. Seidel spent more than a decade at Novartis Institutes for Biomedical Research in senior leadership roles, including Head of the Genomics Institute of the Novartis Research Foundation and Global Head of Business Development & Licensing, where he oversaw a broad range of scientific collaborations and strateg
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Novartis AGM Links Board Refresh And Dividend Growth To Future Returns [Yahoo! Finance]Yahoo! Finance
- Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa [Yahoo! Finance]Yahoo! Finance
- Peanut Allergy Market Analysis Report 2025-2035: PALFORZIA and Xolair Approvals, Improved Diagnosis and Innovative Drug Delivery Platforms Drive Growth [Yahoo! Finance]Yahoo! Finance
- Lilly unveils $3 billion production expansion in China [Yahoo! Finance]Yahoo! Finance
- Novartis (NVS) was upgraded by Argus from "hold" to "buy". They now have a $180.00 price target on the stock.MarketBeat
NVS
Earnings
- 2/4/26 - Beat
NVS
Sec Filings
- 2/12/26 - Form 144
- 2/9/26 - Form 144
- 2/4/26 - Form S-8
- NVS's page on the SEC website